Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.00% | -0.38% | 1.84% | -19.04% | -31.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.00% | -0.38% | 1.84% | -19.04% | -31.79% |
| Cost of Revenue | 20.55% | 29.64% | 27.42% | -22.40% | -44.57% |
| Gross Profit | -5.24% | -10.35% | -6.57% | -17.57% | -25.05% |
| SG&A Expenses | -2.60% | -6.65% | -8.93% | -15.90% | -28.93% |
| Depreciation & Amortization | -23.68% | -12.88% | 0.00% | -6.92% | -13.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.94% | -0.22% | -1.20% | -17.12% | -32.45% |
| Operating Income | 81.55% | -8.32% | 349.03% | -58.88% | 46.76% |
| Income Before Tax | -900.17% | -843.71% | -32.44% | 130.70% | 84.59% |
| Income Tax Expenses | -78.77% | -98.74% | -79.60% | -35.36% | 90.26% |
| Earnings from Continuing Operations | -528.43% | -236.62% | -13.27% | 120.00% | 76.33% |
| Earnings from Discontinued Operations | 108.70% | 110.41% | 118.65% | 67.34% | 10.23% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -366.29% | -109.14% | 14.40% | 111.98% | 70.87% |
| EBIT | 81.55% | -8.32% | 349.03% | -58.88% | 46.76% |
| EBITDA | 11.70% | -21.55% | 6.64% | -36.13% | -6.93% |
| EPS Basic | -220.34% | -69.28% | 33.83% | 107.62% | 75.98% |
| Normalized Basic EPS | -602.10% | -254.33% | 73.33% | 194.74% | 111.66% |
| EPS Diluted | -118.32% | -98.15% | -9.14% | 60.87% | 56.51% |
| Normalized Diluted EPS | -1,353.85% | -493.35% | 47.49% | 167.93% | 105.33% |
| Average Basic Shares Outstanding | 38.75% | 25.33% | 13.42% | 15.85% | 23.76% |
| Average Diluted Shares Outstanding | 54.88% | 66.69% | 47.07% | 51.90% | 52.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |